Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Hahn

Showing results (181-190 of 210) with videos related to

Pageof 21
Sort By:
The Journal of Clinical Investigation|July 28, 2015
GATA2 is required for lymphatic vessel valve development and maintenanceJan Kazenwadel, Kelly L Betterman, Chan-Eng Chong, et al.
Pathology|August 28, 2022
Novel modes of MPL activation in triple-negative myeloproliferative neoplasmsSaumya E Samaraweera, Tatjana Geukens, Debora A Casolari, et al.
Blood Advances|May 22, 2025
RAS mutation identifies a poor prognostic molecular subtype of therapy-related myeloid neoplasmChung Hoow Kok, Aref Al-Kali, Daniel Thomas, et al.
Molecular Psychiatry|December 21, 2011
Transcriptome profiling of UPF3B/NMD-deficient lymphoblastoid cells from patients with various forms of intellectual disabilityL S Nguyen, L Jolly, C Shoubridge, et al.
Blood|September 7, 2013
Regulation of vascular leak and recovery from ischemic injury by general and VE-cadherin-restricted miRNA antagonists of miR-27Jennifer A Young, Ka Ka Ting, Jia Li, et al.
Scientific Reports|May 28, 2017
A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasmD A Casolari, T Nguyen, C M Butcher, et al.
Data in Brief|March 10, 2016
In depth analysis of the Sox4 gene locus that consists of sense and natural antisense transcriptsKing-Hwa Ling, Peter J Brautigan, Sarah Moore, et al.
Leukemia|December 1, 2009
Novel RUNX1 mutations in familial platelet disorder with enhanced risk for acute myeloid leukemia: clues for improved identification of the FPD/AML syndromeM C J Jongmans, R P Kuiper, C L Carmichael, et al.
Blood Cancer Journal|April 11, 2023
TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasmsMithun Vinod Shah, Elizabeth Ngoc Hoa Tran, Syed Shah, et al.
Leukemia|March 10, 2015
A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant cloneC N Hahn, D M Ross, J Feng, et al.
Pageof 21

Showing results (181-190 of 210) with videos related to

Sort By:
Pageof 21
The Journal of Clinical Investigation|July 28, 2015
GATA2 is required for lymphatic vessel valve development and maintenanceJan Kazenwadel, Kelly L Betterman, Chan-Eng Chong, et al.
Pathology|August 28, 2022
Novel modes of MPL activation in triple-negative myeloproliferative neoplasmsSaumya E Samaraweera, Tatjana Geukens, Debora A Casolari, et al.
Blood Advances|May 22, 2025
RAS mutation identifies a poor prognostic molecular subtype of therapy-related myeloid neoplasmChung Hoow Kok, Aref Al-Kali, Daniel Thomas, et al.
Molecular Psychiatry|December 21, 2011
Transcriptome profiling of UPF3B/NMD-deficient lymphoblastoid cells from patients with various forms of intellectual disabilityL S Nguyen, L Jolly, C Shoubridge, et al.
Blood|September 7, 2013
Regulation of vascular leak and recovery from ischemic injury by general and VE-cadherin-restricted miRNA antagonists of miR-27Jennifer A Young, Ka Ka Ting, Jia Li, et al.
Scientific Reports|May 28, 2017
A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasmD A Casolari, T Nguyen, C M Butcher, et al.
Data in Brief|March 10, 2016
In depth analysis of the Sox4 gene locus that consists of sense and natural antisense transcriptsKing-Hwa Ling, Peter J Brautigan, Sarah Moore, et al.
Leukemia|December 1, 2009
Novel RUNX1 mutations in familial platelet disorder with enhanced risk for acute myeloid leukemia: clues for improved identification of the FPD/AML syndromeM C J Jongmans, R P Kuiper, C L Carmichael, et al.
Blood Cancer Journal|April 11, 2023
TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasmsMithun Vinod Shah, Elizabeth Ngoc Hoa Tran, Syed Shah, et al.
Leukemia|March 10, 2015
A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant cloneC N Hahn, D M Ross, J Feng, et al.
Pageof 21